

- 1 **Title** A protocol for a systematic review with prospective individual patient data meta-analysis in
- 2 EGFR mutant NSCLC with brain metastases to assess the effect of SRS + Osimertinib compared to
- 3 Osimertinib alone: the STARLET collaboration.
  
- 4 **Author names**
  
- 5 Dr Kristy P Robledo\*, NHMRC Clinical Trials Centre, University of Sydney, Australia;
- 6 [Kristy.robledo@sydney.edu.au](mailto:Kristy.robledo@sydney.edu.au)
  
- 7 Dr Shilo Lefresne, BC Cancer Agency, Canada [SLefresne@bccancer.bc.ca](mailto:SLefresne@bccancer.bc.ca)
  
- 8 Dr Yu Yang, National University Cancer Institute Singapore, [yu\\_yang\\_soon@nuhs.edu.sg](mailto:yu_yang_soon@nuhs.edu.sg)
  
- 9 Dr Arjun Sahgal, Sunnybrook Health Science Centre, Canada, [Arjun.Sahgal@sunnybrook.ca](mailto:Arjun.Sahgal@sunnybrook.ca)
  
- 10 A/Prof Mark B Pinkham, University of Queensland and Princess Alexandra Hospital, Australia
- 11 [Mark.Pinkham@health.qld.gov.au](mailto:Mark.Pinkham@health.qld.gov.au)
  
- 12 Prof Alan Nichol, BC Cancer Agency, Canada, [anichol@bccancer.bc.ca](mailto:anichol@bccancer.bc.ca)
  
- 13 Dr Ross Andrew Soo, National University Cancer Institute Singapore [ross\\_soo@nuhs.edu.sg](mailto:ross_soo@nuhs.edu.sg)
  
- 14 Dr Ambika Parmar, Sunnybrook Health Sciences Centre, Canada [ambika.parmar@sunnybrook.ca](mailto:ambika.parmar@sunnybrook.ca)
  
- 15 Dr Fiona Hegi-Johnson, Peter MacCallum Cancer Centre, Australia [Fiona.Hegi-](mailto:Fiona.Hegi-Johnson@petermac.org)
- 16 [Johnson@petermac.org](mailto:Johnson@petermac.org)
  
- 17 Dr Mark Doherty, St Vincents University Hospital, Ireland, [mdoherty@svcpc.ie](mailto:mdoherty@svcpc.ie)
  
- 18 Prof Benjamin J Solomon, Peter MacCallum Cancer Centre, Australia [Ben.solomon@petermac.org](mailto:Ben.solomon@petermac.org)
  
- 19 Dr David Shultz, Princess Margaret Cancer Centre, Canada [david.shultz@rmp.uhn.ca](mailto:david.shultz@rmp.uhn.ca)
  
- 20 Dr Ivan WK Tham, Mt Elizabeth Novena Hospital, Singapore [ivan.tham@ihhhealthcare.com](mailto:ivan.tham@ihhhealthcare.com)
  
- 21 Dr Adrian Sacher, Princess Margaret Cancer Centre, Canada [Adrian.Sacher@uhn.ca](mailto:Adrian.Sacher@uhn.ca)

- 22 Dr Jeremy Tey, National University Cancer Institute Singapore [jeremy\\_tey@nuhs.edu.sg](mailto:jeremy_tey@nuhs.edu.sg),
- 23 Dr Cheng Nang Leong, National University Cancer Institute Singapore
- 24 [Cheng\\_Nang\\_Leong@nuhs.edu.sg](mailto:Cheng_Nang_Leong@nuhs.edu.sg)
- 25 Dr Wee Yao Koh, National University Cancer Institute Singapore [wee\\_yao\\_koh@nuhs.edu.sg](mailto:wee_yao_koh@nuhs.edu.sg)
- 26 Dr Yiqing Huang, National University Cancer Institute Singapore [yiqing\\_huang@nuhs.edu.sg](mailto:yiqing_huang@nuhs.edu.sg)
- 27 Dr Yvonne Ang, National University Cancer Institute Singapore [Yvonne\\_ang@nuhs.edu.sg](mailto:Yvonne_ang@nuhs.edu.sg)
- 28 Dr Jiali Low, National University Cancer Institute Singapore [Jiali\\_low@nuhs.edu.sg](mailto:Jiali_low@nuhs.edu.sg)
- 29 Dr Clement Yong, National University Hospital Singapore [clement\\_yong@nuhs.edu.sg](mailto:clement_yong@nuhs.edu.sg)
- 30 Dr Mei Chin Lim, National University Hospital Singapore [mei\\_chin\\_lim@nuhs.edu.sg](mailto:mei_chin_lim@nuhs.edu.sg)
- 31 Dr Ai Peng Tan, National University Hospital, Singapore, [ai\\_peng\\_tan@nuhs.edu.sg](mailto:ai_peng_tan@nuhs.edu.sg)
- 32 A/Prof Chee Khoon Lee, NHMRC Clinical Trials Centre, University of Sydney, Australia
- 33 [chee.lee@sydney.edu.au](mailto:chee.lee@sydney.edu.au)
- 34 Dr Cheryl Ho, BC Cancer Agency, Canada, [CHo@bccancer.bc.ca](mailto:CHo@bccancer.bc.ca)
- 35 On behalf of the oSimertinib with or without sTereotActic Radiosurgery in egfr non-small cell Lung  
36 canceR with brain metastases (STARLET) Collaboration
- 37
- 38 \*Corresponding author; [Kristy.robledo@sydney.edu.au](mailto:Kristy.robledo@sydney.edu.au); 92-94 Parramatta Road, Camperdown, 2050
- 39
- 40 Word count 2728
- 41 Number of figures: 0
- 42 Number of tables: 1

43 **DECLARATIONS**

44 **Ethics approval and consent to participate**

45 IPD will be provided by each included trial on the stipulation that ethical approval has been provided  
46 by their respective Human Research Ethics Committees (or equivalent), and participants gave  
47 informed consent before enrolment. Only trials with ethics approval will be included in these  
48 analyses. Trialists remain the custodians of their own data, which will be de-identified before being  
49 shared with the Collaboration.

50 Each trial contributing data to this project has been approved by ethics committees. OUTRUN (TROG  
51 17.02, NCT03497767) has ethics approval from Melbourne Health Human Research Committee,  
52 Melbourne, Australia and LUOSICNS (NCT03769103) has ethics approval from British Columbia  
53 Cancer Agency Research Ethics Board, University of British Columbia, Canada.

54 **Consent for publication**

55 NA

56 **Availability of data and materials**

57 Data sharing is not applicable to this article as no datasets were generated or analysed during the  
58 current study.

59 **Competing interests**

60 SL: research funding and honoraria from AstraZeneca.

61 YYS: Honoraria: AstraZeneca, Janssen

62 ASah: research grants (Institution) from Elekta AB, Varian, Seagen Inc and BrainLAB. Consulting fees  
63 from Varian, Elekta (Gamma Knife Icon), BrainLAB, Merck, Abbvie and Roche. Honoraria:  
64 AstraZeneca, Elekta AB, Varian, BrainLAB, Accuray, Seagen Inc.

- 65 MBP: speaker fees AZ, BMS, MSD, Roche.
- 66 AN: research grants from Varian Medical Systems Ltd.
- 67 RAS: advisory board: Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Janssen, Lily, Merck,  
68 Merck Serono, Novartis, Pfizer, Puma Biotechnology, Roche, Taiho, Takeda, Thermo Fisher, Yuhan  
69 Corporation, research grant: Astra-Zeneca, Boehringer Ingelheim
- 70 FHJ: clinical trial funding, received honoraria and participated in advisory boards for Astra Zeneca.  
71 She has received payments and honoraria from BeiGene and MSD for lectures and presentations.  
72 Her work is supported by the Peter Mac Foundation and the Victorian Cancer Agency.
- 73 BJS: Advisory Board/Honoraria from AstraZeneca, Pfizer, Novartis, Roche, Takeda, Merck, Bristol  
74 Myers Squibb, Janssen, Amgen, Eli Lilly
- 75 IT: Honorarium Elekta, MSD
- 76 CH: advisory boards with Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz,  
77 Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, research grants: AstraZeneca, EMD Serono, Roche
- 78 CKL: Advisory board: Amgen, Astra Zeneca, GSK, Merck KGA, Novartis, Pfizer, Roche, Takeda,  
79 Boehringer-Ingelheim, Yuhan. Research Funding (Institution): Astra Zeneca, Roche, Merck KGA,  
80 Amgen
- 81 KR, AP, MD, DS, ASac, JT, CNL, WYK, YH, YA, JL, CY, MCL, and APT have no competing interests. CH,  
82 SL, FHJ, CKL, YY, RAS and IT are study chairs on the included trials.

### 83 **Funding**

- 84 OUTRUN was supported by the following: Sponsored by Trans Tasman Radiation Oncology Group  
85 (TROG) Cancer Research, ESR funding from AstraZeneca, National University Health System (NUHS)  
86 Seed Fund, NUHSRO/2019/053/RO5+5/Seed-Mar/06), National University Health System (NUHS)  
87 Medical Research Application (HREF) - Cancer Fund, National University Cancer Institute, Singapore

88 (Gift from Mr Sajiv Misra via Phoenix Advisers Pte Ltd), The Royal Australian New Zealand College of  
89 Radiologists (RANZCR) Research Grant.

90 LUOSICNS was supported by ESR funding from AstraZeneca.

#### 91 **Authors Contributions**

92 KR, CKL, YY, FHJ, CH, AN and SL conceived the idea for this study. KR, YY, CKL, FHJ, MP, RS, CH, AN  
93 and SL developed the research question and protocol registration. KR wrote the first draft of the  
94 manuscript. KR and YY developed the eligibility and search strategy, and performed the search and  
95 screening. All authors critically reviewed and provided feedback on the intellectual content of the  
96 manuscript and agreed and approved the final version.

#### 97 **Acknowledgements**

98 We would like to thank AstraZeneca for their ongoing support of both clinical trials. We would also  
99 like to thank Cancer Australia for their support for OUTRUN.

100 YYS: Supported by the National Medical Research Council (NMRC/MOH/000396)

101

102

#### 103 **KEYWORDS**

104 Individual participant data meta-analysis, EGFR mutant NSCLC, stereotactic radiosurgery,  
105 Osimertinib, brain metastases

106

107

108

109

110 **ABSTRACT:** 268/350 words

111 **Background:** Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in  
112 the epidermal growth factor receptor (*EGFR*) gene are a heterogenous population who often  
113 develop brain metastases (BM). The optimal management of patients with asymptomatic brain  
114 metastases is unclear given the activity of newer generation targeted therapies in the central  
115 nervous system. We present a protocol for an individual patient data prospective meta-analysis (IPD-  
116 PMA) to evaluate whether the addition of stereotactic radiosurgery (SRS) before Osimertinib  
117 treatment will lead to better control of intracranial metastatic disease. This is a clinically relevant  
118 question that will inform practice.

119 **Methods:** Randomised controlled trials (RCTs) will be eligible if they included: participants with BM  
120 arising from *EGFR* mutant NSCLC and suitable to receive Osimertinib both in the first- and second-  
121 line settings (P); comparisons of SRS followed by Osimertinib versus Osimertinib alone (I, C); and  
122 intracranial disease control included as an endpoint (O). Systematic searches of Medline (Ovid),  
123 Embase (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO),  
124 PsychInfo, ClinicalTrials.gov and the World Health Organisation's International Clinical Trials Registry  
125 Platform's Search Portal will be undertaken. An IPD meta-analysis will be performed using  
126 methodologies recommended by the Cochrane Collaboration. The primary outcome is intra-cranial  
127 progression free survival, as determined by RANO-BM criteria. Secondary outcomes include overall  
128 survival, time to whole brain radiotherapy, quality of life and adverse events of special interest.  
129 Effect differences will be explored among pre-specified subgroups.

130 **Ethics and dissemination:** Approved by each trials ethics committee. Results will be relevant to  
131 clinicians, researchers, policymakers and patients, and will be disseminated via publications,  
132 presentations and media releases.

133 **Prospero registration:** CRD42022330532

134

### 135 **Strengths and Limitations of this study**

136 • The use of an individual patient data (IPD) meta-analysis will give increased statistical power  
137 for the relative comparison of SRS followed by Osimertinib versus Osimertinib alone on intracranial  
138 progression-free survival. Such a meta-analysis will also enable the exploration of subgroups.

139 • Frequency of outcome assessment and outcome measures may be collected and reported  
140 differently across included trials, which may lead to some imprecision. Harmonisation of clinical trial  
141 protocols through prospective meta-analysis will address some of these limitations.

142 • A limitation of this study is that the searches will only be conducted until late 2023 and any  
143 studies that are registered after this time will not be included.

144

### 145 **Abbreviations**

146 AESI           adverse events of special interest

147 ASCO           American Society of Clinical Oncology

148 ASTRO         American Society for Radiation Oncology

149 BM             brain metastases

150 *EGFR*         epidermal growth factor receptor

151 FDA            U.S. Food and Drug Administration

152 GRADE         Grading of Recommendations Assessment, Development and Evaluation ()

153 ic-PFS         intracranial disease progression-free survival

154 IPD            individual patient data

155 NSCLC Non-small-cell lung cancer

156 OS overall survival

157 PRISMA-P Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)

158 extension for protocols (P)

159 RCT randomised controlled trial

160 SNO Society for Neuro-Oncology

161 SRS Stereotactic radiosurgery

162 STARLET oSimertinib with or without sTereotActic Radiosurgery in egfr non-small cell Lung

163 canceR with brain metastases

164 TKI tyrosine kinase inhibitors

165

166

167

168

169

170

171

172

173

174

175

176 **INTRODUCTION**

177 Non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor  
178 receptor (*EGFR*) gene is a distinct subtype that is characterised by a high tumour response rate when  
179 treated with small molecule *EGFR* tyrosine kinase inhibitors (TKIs). Approximately 20% to 40% of  
180 patients with advanced NSCLC will develop brain metastases (BM) at some point during their disease  
181 course, and it is possible that patients with *EGFR* mutant NSCLC at greater risk due to improved  
182 survival (1, 2).

183 Stereotactic radiosurgery (SRS) involves the precise delivery of high doses of ionising radiation over a  
184 single or limited number of fractions to an intracranial target (3). Based on populations with BM  
185 from predominantly NSCLC but not enriched for *EGFR*, incorporating SRS in the management of BM  
186 was associated with improvement in overall survival (OS) for those with a single lesion and  
187 prolongation of functional independence in those with up to 3 BM (4). However, the detrimental  
188 effects of whole brain radiation are now well known such that SRS alone has become the standard of  
189 care. Use of SRS alone for multiple BM has been adopted routinely (5), in particular, given the  
190 prospective Japanese observational study involving patients with up to 10 BM demonstrated that  
191 OS of patients with 5-10 brain metastases treated with SRS alone was non-inferior to those with 2-4  
192 brain metastases (6). Hence for patients with a good performance status, the American Society for  
193 Radiation Oncology (ASTRO) strongly recommends SRS for those with 1 to 4 BM and also  
194 conditionally recommends this treatment for those with 5 to 10 BM (7).

195 Osimertinib is an oral 3rd generation irreversible mutant selective, wild type sparing *EGFR* TKI with a  
196 higher central nervous system penetration and intracranial activity than first-generation *EGFR* TKIs.  
197 It has been approved by the U.S. Food and Drug Administration (FDA) as a first line treatment for  
198 *EGFR* mutant NSCLC based on the FLAURA trial(8, 9), as well as second line treatment for those who  
199 have developed a T790M mutation after exposure to first generation *EGFR* TKI based on the AURA 3  
200 trial (10). In subset analyses, patients with stable, asymptomatic BM had significantly prolonged

201 intracranial disease progression-free survival (ic-PFS) with Osimertinib compared to Gefitinib or  
202 Erlotinib in the FLAURA trial (11) and platinum-pemetrexed in the AURA3 trial (12). However, the  
203 true intracranial activity of Osimertinib remains unclear as a significant number of patients enrolled  
204 in these trials had prior cranial radiotherapy (24% in FLAURA and 41% in AURA3). Notably, the  
205 OCEAN trial, a single arm phase two study of with T790M positive *EGFR* mutant NSCLC and  
206 untreated BM, found the intracranial response rate for second line Osimertinib was 67% and median  
207 ic-PFS was 25 months (13).

208 Currently, the optimal sequencing of SRS and Osimertinib in patients with *EGFR* mutant NSCLC and  
209 untreated BM is unclear. The American Society of Clinical Oncology (ASCO)- Society for Neuro-  
210 Oncology (SNO)-ASTRO guideline states that local therapy may be delayed in selective patients with  
211 asymptomatic BM from *EGFR* mutant NSCLC, however the strength of the recommendation is weak  
212 as the quality of evidence supporting this recommendation is low (14). There is conflicting evidence  
213 from retrospective cohort studies. Magnuson and colleagues found that those who received upfront  
214 cranial irradiation had longer OS than those who received upfront first-generation *EGFR* TKI with  
215 deferred cranial irradiation (15). Similarly, Yu and colleagues observed that upfront cranial  
216 radiotherapy was associated with reduced cumulative incidence of ic-PFS in the entire cohort  
217 receiving Osimertinib and improvement in OS in a subset of patients with 1-3 BM (16). However,  
218 Thomas and colleagues did not find any improvement (17).

219 Two phase II randomised controlled trials (RCTs), OUTRUN (TROG 17.02) (18) and LUOSICNS (19) are  
220 independently recruiting participants with BM from *EGFR* mutant NSCLC to evaluate whether SRS  
221 followed by Osimertinib is more efficacious than Osimertinib alone in delaying progression of  
222 intracranial disease. OUTRUN completed recruitment in September 2022, and LUOSICNS completed  
223 recruitment in April 2023. Both have a sample size of 40 participants, and individually lack the  
224 statistical power to formally compare differences between treatment arms. They are hypothesis-  
225 generating to inform planning of a future definitive phase III RCT.

226 Therefore, we have developed a collaboration, STARLET (Osimertinib with or without Stereotactic  
227 Radiosurgery in EGFR non-small cell Lung cancer with brain metastases), to prospectively conduct an  
228 individual patient data (IPD) meta-analysis of these RCTs to compare the effects of SRS followed by  
229 Osimertinib versus Osimertinib alone followed by deferred local cranial therapies on intracranial  
230 disease control in patients with BM from *EGFR* mutant NSCLC. The purpose is to establish which  
231 treatment strategy will lead to better control of intracranial disease, and if there are subgroups of  
232 patients that might benefit more from the combination treatment strategies.

233

## 234 **METHODS AND ANALYSIS**

235 A systematic review and IPD meta-analysis will be conducted according to the recommended  
236 methods (20, 21). Lead investigators of eligible RCTs will be invited to share their IPD and join this  
237 STARLET collaboration. Online supplementary Appendix 1 lists eligible RCTs identified up to July  
238 2022. This protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-  
239 Analysis (PRISMA) extension for protocols (PRISMA-P, checklist detailed in supplementary Appendix  
240 2) (22) and has been registered on PROSPERO (CRD42022330532). If subsequent potentially eligible  
241 RCTs are published, a nested prospective meta-analysis may be used, in order to combine  
242 retrospective inclusion of these additional trials with the proposed results gained from these  
243 analyses. At this time, there are no consumers actively involved with the collaboration.

244

### 245 **Eligibility criteria**

#### 246 ***Types of studies***

247 STARLET will include RCTs only. Randomisation may occur at the individual level or by cluster and  
248 quasi-randomised trials will be excluded. There are no language or date restrictions.

#### 249 ***Trial participants***

250 Participants will be eligible if they are receiving Osimertinib in the first- or second-line setting. For  
251 those receiving Osimertinib as first line systemic therapy, all newly diagnosed participants must have  
252 a documented sensitising *EGFR* mutation (including exon 19 del, L858R (exon 21), G719X (exon 18),  
253 L861G (exon 21), S768I (exon 20) and T790M (exon 20)) and intracranial metastasis, with or without  
254 extracranial disease. For those receiving Osimertinib as second line systemic therapy, participants  
255 will have developed intracranial metastases while on first-line 1st or 2nd generation *EGFR* TKI  
256 therapy, with no or stable extracranial disease regardless of T790M mutation.

257 Intracranial disease is defined as: (a)  $\leq 10$  lesions visible and measurable on protocol screening MRI,  
258 with at least one BM amenable to SRS; (b) no single BM exceeding 30mm in longest diameter; and  
259 (c) absence of neurologic symptoms except for headache, nausea or seizure which were medically  
260 controlled.

## 261 ***Interventions***

262 One intervention is SRS followed by Osimertinib. The SRS dose-fractionation schedule depends on  
263 size and location of the lesion. The SRS is to be planned after randomisation, and Osimertinib  
264 commences after the completion of SRS. Osimertinib treatment is described below.

265 The other intervention is Osimertinib alone. Osimertinib will be administered orally as one 80 mg  
266 tablet once a day. A cycle of treatment is defined as 28 days of once daily Osimertinib treatment.

267 For those allocated to Osimertinib alone, treatment with Osimertinib will commence following  
268 randomisation. Participants may continue to receive treatment with Osimertinib as long as they are  
269 continuing to show clinical benefit, as judged by the treating clinician, and within the guidelines of  
270 the relevant trial protocol's discontinuation criteria.

271

## 272 **Information sources and search strategy**

273 We searched the following databases from their inception: Medline (Ovid), Embase (Ovid), Cochrane  
274 Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO), PsychInfo, ClinicalTrials.gov and the  
275 World Health Organisation's International Clinical Trials Registry Platform's Search Portal. The full  
276 search strategy is available in **Online Supplementary Appendix 2**. The initial search was completed  
277 up to July 2022, and will be updated regularly to search for new trials until late-2023. Collaborators  
278 and contacts were asked to notify us of any additional planned, or ongoing completed trials that may  
279 fulfil eligibility criteria. At this time, only the two aforementioned trials (OUTRUN, TROG 17.02:  
280 NCT03497767 and LUOSICNS: NCT03769103) have been identified, and both trial teams have agreed  
281 to share IPD for this collaboration.

### 282 ***Selection of studies for inclusion in the review***

283 Two members of the STARLET Collaboration will independently screen all future retrieved records  
284 against eligibility criteria. Any discrepancies will be resolved by consensus or, if required,  
285 adjudication by a third reviewer. The Principal Investigator and/or corresponding author of any  
286 additional eligible studies will be invited to join the STARLET Collaboration. If there is no response to  
287 initial emails, we will contact other co-authors or contacts listed on registration records. If IPD are  
288 not available for an eligible trial, we will use aggregate data where possible.

289

### 290 **Data collection, management, and confidentiality**

#### 291 ***Data receipt / extraction***

292 De-identified IPD will be shared via secure data transfer platforms or via institutional secure email  
293 using password-protected zip files. Data will be provided according to a pre-specified coding  
294 template where possible, otherwise, data will be accepted in any format and recoded as necessary.  
295 The data management team will receive and store the data in perpetuity in a secure, customised  
296 database at the NHMRC Clinical Trials Centre, University of Sydney, and data management will

297 follow the University of Sydney's Data Management Policies. Each trial team will also be asked to  
298 provide metadata (such as questionnaires, data collection forms, and data dictionaries) to aid  
299 understanding of the datasets. Trial-level data, such as intervention details (setting, timing and  
300 duration), intervention details, method of sequence generation, allocation concealment,  
301 geographical location, sample size, outcome measures and definitions will be cross-checked against  
302 published reports, trial protocols, registration records and data collection sheets, in order to ensure  
303 data integrity.

#### 304 ***Data processing***

305 IPD from each trial will be checked with respect to range, internal consistency, consistency with  
306 published reports and missing items. Integrity of the randomisation process will be examined by  
307 reviewing the chronological randomisation sequence and pattern of assignment, as well as the  
308 balance of participant characteristics across intervention and control groups. Any inconsistencies or  
309 missing data will be discussed with trialists/data managers and resolved by consensus. Each included  
310 trial will be analysed individually, and results shared with trialists for verification. Once finalised,  
311 data from each of the trials will be combined into a single database.

#### 312 **Risk of bias assessment and certainty of evidence appraisal**

313 Included studies will be assessed for risk of bias by two reviewers, independently, using the criteria  
314 described in the Cochrane handbook (23): random sequence generation; allocation concealment;  
315 blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data;  
316 selective reporting; and other bias. The quality of evidence will be assessed using the Grading of  
317 Recommendations Assessment, Development and Evaluation (GRADE) approach (24). Any  
318 differences will be resolved by consensus or with a third reviewer.

319

#### 320 **Primary outcome**

321 The primary outcome will be ic-PFS at 12 months, as determined by RANO-BM criteria (25).

### 322 **Secondary outcomes**

323 All outcomes and their definitions are detailed in Table 1. Secondary outcomes include OS, time to  
324 whole brain radiotherapy, quality of life and adverse events of special interest (AESI).

### 325 **Covariates and subgroups**

326 Individual and study-level subgroup analyses will be conducted for ic-PFS. Individual-level  
327 characteristics to be assessed include mutation type (*EGFR* exon19 deletion vs exon 21 L858R vs  
328 uncommon sensitising mutations, pending numbers), line of therapy (first vs second), number of BM  
329 (either: <4 vs ≥4 or 1 vs ≥2, pending total numbers), diameter of largest lesion (≤15mm vs >15mm),  
330 age at baseline (<70 vs ≥70 years), sex (male vs female), country of treatment (Singapore vs  
331 Australia vs Canada), ethnicity (Asian vs other), smoker (never vs ex or current smoker), extracranial  
332 disease presence at baseline (present vs absent), and ECOG performance status (0 vs ≥1). If data are  
333 insufficient for the pre-specified subgroup analyses, categories will be reassessed prior to any  
334 analyses, by consensus of the STARLET collaboration.

### 335 **Data analysis**

336 A detailed statistical analysis plan will be prepared and agreed on by the STARLET Collaboration  
337 members prior to any analyses being undertaken. Analyses will include all randomised participants  
338 who meet the inclusion criteria, for which IPD are available. All analyses will be based on randomised  
339 treatment allocation (intention to treat principle).

340 For the primary outcome of ic-PFS at 12 months, cumulative incidence estimates taking into account  
341 the competing risk of extracranial progression (with their variances) from the trials will be pooled  
342 using inverse variance weighting (two stage approach). Other secondary outcomes will be examined  
343 using Cox regression or linear models, adjusted for study (one stage approach). Heterogeneity of

344 treatment effects across trials will be estimated using  $I^2$ , and investigated by fitting a trial-by-  
345 treatment interaction term to the models. Any heterogeneity identified will be explored further.  
346 Differences in treatment effect between the pre-specified subgroups will be examined by testing a  
347 treatment by subgroup interaction term within a Fine-Gray regression model for ic-PFS, taking into  
348 account competing risks. Findings of subgroup analyses will be reported as exploratory.  
349 Missing data may be explored in sensitivity analyses using multiple imputation. Analyses will be  
350 performed using SAS and the open-source software R (26).

### 351 **Assessment of selection or publication bias**

352 Potential selection bias and publication bias may be investigated by conducting a nested prospective  
353 meta-analysis and comparing trials that were included prospectively versus those identified  
354 retrospectively in a sensitivity analysis (if appropriate). Contour-enhanced funnel plots to examine  
355 whether there are differences in results between more and less precise studies.

### 356 **Adjustments for multiple testing**

357 No formal adjustments will be made for multiple comparisons. However, we will follow Schulz and  
358 Grimes' approach (27) and interpret the patterns and consistency of results across related outcomes  
359 rather than focusing on statistical significance alone.

### 360 **Planned sensitivity analyses**

361 If possible, the following sensitivity analyses will be conducted for the primary outcome; including  
362 published aggregate data combined with IPD in the meta-analysis compared to IPD alone and  
363 including prospectively included trials only. Additional sensitivity analyses may be conducted on  
364 other outcomes to determine the effect of missing data. These will be detailed in the statistical  
365 analysis plan.

366

367 **Project management**

368 Membership of the STARLET Collaboration includes representatives from each of the trials  
369 contributing IPD to the project. Trial representatives have the opportunity to contribute their expert  
370 knowledge to the Collaboration and provide input into the protocols, statistical analysis plan, and  
371 final results manuscript. The STARLET Collaboration will be responsible for data collection,  
372 management and analysis, as well as communication within the Collaboration, including organisation  
373 of virtual or face-to-face collaborator meetings.

374

375 **ETHICS AND DISSEMINATION**

376 ***Ethical considerations***

377 IPD will be provided by each included trial on the stipulation that ethical approval has been provided  
378 by their respective Human Research Ethics Committees (or equivalent), and participants gave  
379 informed consent before enrolment. Only trials with ethics approval will be included in these  
380 analyses. Trialists remain the custodians of their own data, which will be de-identified before being  
381 shared with the Collaboration.

382 ***Publication policy***

383 Manuscripts will be prepared by the relevant members of the STARLET Collaboration, and circulated  
384 for comment, revision and approval prior to submission for publication. Any reports of the results  
385 from this study will be published either in the name of the collaborative group, or by representatives  
386 of the collaborative group on behalf of the STARLET Collaboration, as agreed by all members.

387

388

389

390 **DISCUSSION**

391 An IPD meta-analysis is considered the gold standard of systematic reviews, and has many  
392 advantages over a standard aggregate approach. This includes the collaboration of a range of expert  
393 trialists and biostatisticians in order to ensure that all possible RCTs are included and appropriate  
394 analysis of outcomes are performed. Through prospectively collaborating, STARLET can pre-specify  
395 the patient population, interventions, and outcomes clearly and harmonise trial protocols where  
396 possible. Another clear advantage is the increase in statistical power. The two eligible RCTs  
397 identified at this time are both Phase II RCTs that individually are not powered to identify a  
398 statistically significant difference between treatments, but rather are looking for efficacy signals and  
399 safety of treatment.

400 We will seek to address this with the use of a prospective meta-analysis to include published  
401 aggregate data, and by encouraging planned and ongoing trials to collect our core outcomes and  
402 share data.

403 Based on the recruitment timelines of the two trials identified, we plan to complete study  
404 identification by end of 2023, IPD collection by mid-2024 and conduct the analyses and disseminate  
405 the results by mid-2025. These timelines may be adjusted if follow-up completes early, or if  
406 additional trials are identified and not completed in time to provide data.

407 The results of this systematic review will guide whether a Phase III study is required to inform clinical  
408 practice, and, if so, may help investigators to pre-plan subgroup analyses of interest.

409

410

411

412

413

414     **REFERENCES**

- 415     1.       Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions  
416           of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer  
417           Surveillance System. *Journal of clinical oncology*. 2004;22(14):2865-72.
- 418     2.       Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain  
419           metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.  
420           *Lung Cancer*. 2015;88(1):108-11.
- 421     3.       Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the  
422           management of brain metastases. *Nature Reviews Clinical Oncology*. 2020;17(5):279-99.
- 423     4.       Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain  
424           radiation therapy with or without stereotactic radiosurgery boost for patients with one to  
425           three brain metastases: phase III results of the RTOG 9508 randomised trial. *The Lancet*.  
426           2004;363(9422):1665-72.
- 427     5.       Sahgal A, Ruschin M, Ma L, Verbakel W, Larson D, Brown PD. Stereotactic radiosurgery alone  
428           for multiple brain metastases? A review of clinical and technical issues. *Neuro Oncol*.  
429           2017;19(suppl\_2):ii2-ii15.
- 430     6.       Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic  
431           radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional  
432           prospective observational study. *Lancet Oncol*. 2014;15(4):387-95.
- 433     7.       Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA, et al. Radiation  
434           Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. *Practical Radiation*  
435           *Oncology*. 2022;12(4):265-82.
- 436     8.       Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival  
437           with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *N Engl J Med*.  
438           2020;382(1):41-50.

- 439 9. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al.  
440 Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. *New*  
441 *England Journal of Medicine*. 2018;378(2):113-25.
- 442 10. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or  
443 Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med*. 2017;376(7):629-  
444 40.
- 445 11. Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS Response  
446 to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase  
447 Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer.  
448 *Journal of Clinical Oncology*. 2018;36(33):3290-7.
- 449 12. Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, et al. Phase II Study of Crizotinib in East Asian  
450 Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*.  
451 2018;36(14):1405-11.
- 452 13. Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Mukae H, Ito K, et al. A Phase II Study of  
453 Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results  
454 for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). *J Thorac Oncol*.  
455 2021;16(12):2121-32.
- 456 14. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment  
457 for Brain Metastases: ASCO-SNO-ASTRO Guideline. *J Clin Oncol*. 2022;40(5):492-516.
- 458 15. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, et al. Management of  
459 Brain Metastases in Tyrosine Kinase Inhibitor-Naive Epidermal Growth Factor Receptor-  
460 Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. *J Clin*  
461 *Oncol*. 2017;35(10):1070-7.
- 462 16. Yu F, Ni J, Zeng W, Zhou Y, Guo T, Zeng Y, et al. Clinical Value of Upfront Cranial Radiation  
463 Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell  
464 Lung Cancer With Brain Metastases. *Int J Radiat Oncol Biol Phys*. 2021;111(3):804-15.

- 465 17. Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, et al. Brain Metastases in EGFR- and  
466 ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase  
467 Inhibitors Alone Versus in Combination With Radiation. *J Thorac Oncol.* 2022;17(1):116-29.
- 468 18. A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC  
469 With Brain Metastases. <https://ClinicalTrials.gov/show/NCT03497767>.
- 470 19. Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive  
471 Patients With NSCLC. <https://ClinicalTrials.gov/show/NCT03769103>.
- 472 20. Seidler AL, Hunter KE, Cheyne S, Ghersi D, Berlin JA, Askie L. A guide to prospective meta-  
473 analysis. *Bmj.* 2019;367:l5342.
- 474 21. Tierney JF SL, Clarke M. Chapter 26: Individual participant data. In: Higgins JPT TJ, Chandler J,  
475 Cumpston M, Li T, Page MJ, Welch VA (editors), editor. *Cochrane Handbook for Systematic  
476 Reviews of Interventions version 6.0 (updated July 2019) ed: Cochrane; 2019.*
- 477 22. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting  
478 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.  
479 *Systematic Reviews.* 2015;4(1):1.
- 480 23. Higgins JPT SJ, Page MJ, Elbers RG, Sterne JAC. *Cochrane Handbook for Systematic Reviews  
481 of Interventions: Cochrane, 2022; 2022.*
- 482 24. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.  
483 Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol.*  
484 2011;64(4):383-94.
- 485 25. Luchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of  
486 gefitinib alone without radiation therapy for Japanese patients with brain metastases from  
487 EGFR-mutant lung adenocarcinoma. *Lung Cancer.* 2013;82(2):282-7.
- 488 26. Team RCD. R: A language and environment for statistical computing. Vienna, Austria 2022.
- 489 27. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. *The  
490 Lancet.* 2005;365(9470):1591-5.

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511 Table 1: Outcomes for individual patient data meta-analysis

Outcome	Definition
<b>Primary outcome</b>	
Intracranial progression free survival (iPFS) at 12 months	Time from randomisation to intracranial disease progression, as defined according to RAN-NO
<b>Secondary outcomes</b>	
PFS	Time from randomization to any disease progression
Overall survival	Time from randomization to death
Time to salvage whole brain radiotherapy	Time from randomization to salvage whole brain radiotherapy
Time to salvage SRS	Time from randomization to salvage stereotactic radiotherapy
time to local brain failure	Time from randomization to local brain failure
time to distant progression	Time from randomization to distant disease progression
QOL	QLQ-C30 QLQ-BN 20
Adverse events of special interest	Rates of the following AE (for example): radiation necrosis, neurocognitive impairment, edema cerebral, muscle weakness right side, muscle weakness left side, Fatigue, Gait disturbance, Headache, Seizures, Tremors, Lethargy, Dizziness, Syncope, Stroke and Intracranial hemorrhage

512

513